{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T16:15:46Z","timestamp":1789402546084,"version":"build-2803163510"},"reference-count":122,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,6,20]],"date-time":"2022-06-20T00:00:00Z","timestamp":1655683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,6,20]],"date-time":"2022-06-20T00:00:00Z","timestamp":1655683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1007\/s40261-022-01166-2","type":"journal-article","created":{"date-parts":[[2022,6,20]],"date-time":"2022-06-20T16:03:12Z","timestamp":1655740992000},"page":"567-579","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Pharmacological Anti-Remodelling Effects of Disease-Modifying Drugs in Heart Failure with Reduced Ejection Fraction"],"prefix":"10.1007","volume":"42","author":[{"given":"Michele","family":"Correale","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Mazzeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Tricarico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Croella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martino","family":"Fortunato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Magnesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Amatruda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Alfieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Ferrara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Ceci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Dattilo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Mele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Iacoviello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natale Daniele","family":"Brunetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,20]]},"reference":[{"key":"1166_CR1","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/S0735-1097(99)00630-0","volume":"35","author":"JN Cohn","year":"2000","unstructured":"Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling concepts and clinical implications: a consensus paper from an international forum of cardiac remodeling. J Am Coll Cardiol. 2000;35:569\u201382.","journal-title":"J Am Coll Cardiol"},{"key":"1166_CR2","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1093\/eurheartj\/ehr311","volume":"32","author":"JC Tardif","year":"2011","unstructured":"Tardif JC, O\u2019Meara E, Komajda M, B\u00f6hm M, Borer JS, Ford I, SHIFT Investigators, et al. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. Eur Heart J. 2011;32:2507\u201315.","journal-title":"Eur Heart J"},{"key":"1166_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.665797","volume":"8","author":"M Correale","year":"2021","unstructured":"Correale M, Tricarico L, Fortunato M, Mazzeo P, Nodari S, Di Biase M, et al. New targets in heart failure drug therapy. Front Cardiovasc Med. 2021;8: 665797.","journal-title":"Front Cardiovasc Med."},{"key":"1166_CR4","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M, ESC Scientific Document Group, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42:3599\u2013726.","journal-title":"Eur Heart J"},{"issue":"131","key":"1166_CR5","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1042\/CS20171167","volume":"24","author":"QQ Wu","year":"2017","unstructured":"Wu QQ, Xiao Y, Yuan Y, Ma ZG, Liao HH, Liu C, et al. Mechanisms contributing to cardiac remodeling. Clin Sci. 2017;24(131):2319\u201345.","journal-title":"Clin Sci"},{"key":"1166_CR6","doi-asserted-by":"publisher","first-page":"3920195","DOI":"10.1155\/2017\/3920195","volume":"2017","author":"L Schirone","year":"2017","unstructured":"Schirone L, Forte M, Palmerio S, Yee D, Nocella C, Angelini F, et al. A review of the molecular mechanism underlying the development and progression of cardiac remodeling. Oxid Med Cell Longev. 2017;2017:3920195.","journal-title":"Oxid Med Cell Longev"},{"key":"1166_CR7","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1161\/CIRCULATIONAHA.113.001878","volume":"128","author":"JS Burchfield","year":"2013","unstructured":"Burchfield JS, Xie M, Hill JA. Pathological ventricular remodeling: mechanisms: part 1 of 2. Circulation. 2013;128:388\u2013400.","journal-title":"Circulation"},{"key":"1166_CR8","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/nature09782","volume":"469","author":"B Levine","year":"2011","unstructured":"Levine B, Mizushima N, Virgin HW. Autophagy in immunity and inflammation. Nature. 2011;469:323\u201335.","journal-title":"Nature"},{"key":"1166_CR9","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1093\/cvr\/cvn243","volume":"81","author":"GW Dorn 2nd","year":"2009","unstructured":"Dorn GW 2nd. Apoptotic and non-apoptotic programmed cardiomyocyte death in ventricular remodelling. Cardiovasc Res. 2009;81:465\u201373.","journal-title":"Cardiovasc Res"},{"key":"1166_CR10","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1083\/jcb.201101100","volume":"194","author":"PA Harvey","year":"2011","unstructured":"Harvey PA, Leinwand LA. The cell biology of disease: cellular mechanisms of cardiomyopathy. J Cell Biol. 2011;194:355\u201365.","journal-title":"J Cell Biol"},{"key":"1166_CR11","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S0092-8674(00)81573-1","volume":"93","author":"JD Molkentin","year":"1998","unstructured":"Molkentin JD, Lu JR, Antos CL, Markham B, Richardson J, Robbins J, et al. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell. 1998;93:215\u201328.","journal-title":"Cell"},{"key":"1166_CR12","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s10741-009-9146-x","volume":"14","author":"SE Lehnart","year":"2009","unstructured":"Lehnart SE, Maier LS, Hasenfuss G. Abnormalities of calcium metabolism and myocardial contractility depression in the failing heart. Heart Fail Rev. 2009;14:213\u201324.","journal-title":"Heart Fail Rev"},{"key":"1166_CR13","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1161\/01.RES.0000150369.68826.2f","volume":"95","author":"K Chen","year":"2004","unstructured":"Chen K, Mehta JL, Li D, Joseph L, Joseph J. Transforming growth factor beta receptor endoglin is expressed in cardiac fibroblasts and modulates profibrogenic actions of angiotensin II. Circ Res. 2004;95:1167\u201373.","journal-title":"Circ Res"},{"key":"1166_CR14","doi-asserted-by":"publisher","first-page":"196","DOI":"10.3109\/08977194.2011.595714","volume":"29","author":"A Biernacka","year":"2011","unstructured":"Biernacka A, Dobaczewski M, Frangogiannis NG. TGF-\u03b2 signaling in fibrosis. Growth Factors. 2011;29:196\u2013202.","journal-title":"Growth Factors"},{"key":"1166_CR15","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1161\/CIRCULATIONAHA.112.097832","volume":"125","author":"RM Mortensen","year":"2012","unstructured":"Mortensen RM. Immune cell modulation of cardiac remodeling. Circulation. 2012;125:1597\u2013600.","journal-title":"Circulation"},{"key":"1166_CR16","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s10741-012-9365-4","volume":"19","author":"AM Segura","year":"2014","unstructured":"Segura AM, Frazier OH, Buja LM. Fibrosis and heart failure. Heart Fail Rev. 2014;19:173\u201385.","journal-title":"Heart Fail Rev"},{"key":"1166_CR17","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1093\/cvr\/cvs111","volume":"95","author":"E Yu","year":"2012","unstructured":"Yu E, Mercer J, Bennett M. Mitochondria in vascular disease. Cardiovasc Res. 2012;95:173\u201382.","journal-title":"Cardiovasc Res"},{"key":"1166_CR18","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1161\/CIRCULATIONAHA.104.524835","volume":"112","author":"M Ikeuchi","year":"2005","unstructured":"Ikeuchi M, Matsusaka H, Kang D, Matsushima S, Ide T, Kubota T, et al. Overexpression of mitochondrial transcription factor a ameliorates mitochondrial deficiencies and cardiac failure after myocardial infarction. Circulation. 2005;112:683\u201390.","journal-title":"Circulation"},{"key":"1166_CR19","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1056\/NEJMra063052","volume":"356","author":"S Neubauer","year":"2007","unstructured":"Neubauer S. The failing heart: an engine out of fuel. N Engl J Med. 2007;356:1140\u201351.","journal-title":"N Engl J Med"},{"key":"1166_CR20","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1161\/CIRCRESAHA.110.232306","volume":"108","author":"DF Dai","year":"2011","unstructured":"Dai DF, Johnson SC, Villarin JJ, Chin MT, Nieves-Cintr\u00f3n M, Chen T, et al. Mitochondrial oxidative stress mediates angiotensin II-induced cardiac hypertrophy and Galphaq overexpression-induced heart failure. Circ Res. 2011;108:837\u201346.","journal-title":"Circ Res"},{"key":"1166_CR21","doi-asserted-by":"publisher","first-page":"382","DOI":"10.3389\/fphys.2018.00382","volume":"9","author":"VFM Segers","year":"2018","unstructured":"Segers VFM, Brutsaert DL, De Keulenaer GW. Cardiac remodeling: endothelial cells have more to say than just NO. Front Physiol. 2018;9:382.","journal-title":"Front Physiol"},{"key":"1166_CR22","first-page":"95","volume":"28","author":"Y Wang","year":"2019","unstructured":"Wang Y, Wang C, Ma J. Role of cardiac endothelial cells-derived microRNAs in cardiac remodeling. Discov Med. 2019;28:95\u2013105.","journal-title":"Discov Med"},{"key":"1166_CR23","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.jcmg.2010.10.008","volume":"4","author":"MA Konstam","year":"2011","unstructured":"Konstam MA, Kramer DG, Patel AR, Maron MS, Udelson JE. Left ventricular remodeling in heart failure: current concepts in clinical significance and assessment. JACC Cardiovasc Imaging. 2011;4:98\u2013108.","journal-title":"JACC Cardiovasc Imaging"},{"key":"1166_CR24","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s12872-021-01889-8","volume":"21","author":"S Meng","year":"2021","unstructured":"Meng S, Zhu Y, Liu K, Jia R, Nan J, Chen M, et al. The stress hyperglycaemia ratio is associated with left ventricular remodelling after first acute ST-segment elevation myocardial infarction. BMC Cardiovasc Disord. 2021;21:72.","journal-title":"BMC Cardiovasc Disord"},{"key":"1166_CR25","doi-asserted-by":"publisher","first-page":"29","DOI":"10.15420\/ecr.2015:9:3","volume":"11","author":"DV Cokkinos","year":"2016","unstructured":"Cokkinos DV, Belogianneas C. Left ventricular remodelling: a problem in search of solutions. Eur Cardiol. 2016;11:29\u201335.","journal-title":"Eur Cardiol."},{"key":"1166_CR26","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.jacc.2007.03.034","volume":"50","author":"G Ndrepepa","year":"2007","unstructured":"Ndrepepa G, Mehilli J, Martinoff S, Schwaiger M, Sch\u00f6mig A, Kastrati A. Evolution of left ventricular ejection fraction and its relationship to infarct size after acute myocardial infarction. J Am Coll Cardiol. 2007;50:149\u201356.","journal-title":"J Am Coll Cardiol"},{"key":"1166_CR27","doi-asserted-by":"publisher","first-page":"3014","DOI":"10.1002\/ehf2.13396","volume":"8","author":"A Aimo","year":"2021","unstructured":"Aimo A, Fabiani I, Vergaro G, Arzilli C, Chubuchny V, Pasanisi EM, et al. Prognostic value of reverse remodelling criteria in heart failure with reduced or mid-range ejection fraction. ESC Heart Fail. 2021;8:3014\u201325.","journal-title":"ESC Heart Fail."},{"key":"1166_CR28","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.ijcard.2015.02.019","volume":"184","author":"J Lup\u00f3n","year":"2015","unstructured":"Lup\u00f3n J, Gaggin HK, de Antonio M, Domingo M, Gal\u00e1n A, Zamora E, et al. Biomarker-assist score for reverse remodeling prediction in heart failure: the ST2-R2 score. Int J Cardiol. 2015;184:337\u201343.","journal-title":"Int J Cardiol"},{"key":"1166_CR29","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1253\/circj.CJ-21-0183","volume":"85","author":"N Iwahashi","year":"2021","unstructured":"Iwahashi N, Kirigaya J, Gohbara M, Abe T, Horii M, Hanajima Y, et al. Global strain measured by three-dimensional speckle tracking echocardiography is a useful predictor for 10-year prognosis after a first ST-elevation acute myocardial infarction. Circ J. 2021;85:1735\u201343.","journal-title":"Circ J"},{"key":"1166_CR30","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1093\/ejechocard\/jer177","volume":"12","author":"SM Park","year":"2011","unstructured":"Park SM, Kim YH, Ahn CM, Hong SJ, Lim DS, Shim WJ. Relationship between ultrasonic tissue characterization and myocardial deformation for prediction of left ventricular reverse remodelling in non-ischaemic dilated cardiomyopathy. Eur J Echocardiogr. 2011;12:887\u201394.","journal-title":"Eur J Echocardiogr"},{"key":"1166_CR31","first-page":"iii13","volume":"10 Suppl. 3","author":"NA Marsan","year":"2008","unstructured":"Marsan NA, Breithardt OA, Delgado V, Bertini M, Tops LF. Predicting response to CRT: the value of two- and three-dimensional echocardiography. Europace. 2008;10 Suppl. 3:iii13\u20139.","journal-title":"Europace"},{"key":"1166_CR32","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1148\/radiology.177.2.2217796","volume":"177","author":"D Matthaei","year":"1990","unstructured":"Matthaei D, Haase A, Henrich D, Duhmke E. Cardiac and vascular imaging with an MR snapshot technique. Radiology. 1990;177:527\u201332.","journal-title":"Radiology"},{"key":"1166_CR33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00395-015-0518-1","volume":"111","author":"L Vanhoutte","year":"2016","unstructured":"Vanhoutte L, Gerber BL, Gallez B, Po C, Magat J, Jean-Luc B, et al. High field magnetic resonance imaging of rodents in cardiovascular research. Basic Res Cardiol. 2016;111:1\u201320.","journal-title":"Basic Res Cardiol"},{"key":"1166_CR34","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1002\/(SICI)1522-2594(200002)43:2<177::AID-MRM3>3.0.CO;2-1","volume":"43","author":"M Weiger","year":"2000","unstructured":"Weiger M, Pruessmann KP, Boesiger P. Cardiac real-time imaging using SENSE. Magn Reson Med. 2000;43:177\u201384.","journal-title":"Magn Reson Med"},{"key":"1166_CR35","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1016\/j.ijcard.2013.01.043","volume":"168","author":"K Kida","year":"2013","unstructured":"Kida K, Yoneyama K, Kobayashi Y, Takano M, Akashi YJ, Miyake F. Late gadolinium enhancement on cardiac magnetic resonance images predicts reverse remodeling in patients with nonischemic cardiomyopathy treated with carvedilol. Int J Cardiol. 2013;168:1588\u20139.","journal-title":"Int J Cardiol"},{"key":"1166_CR36","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.ijcard.2017.10.043","volume":"250","author":"A Barison","year":"2018","unstructured":"Barison A, Aimo A, Ortalda A, Todiere G, Grigoratos C, Passino C, et al. Late gadolinium enhancement as a predictor of functional recovery, need for defibrillator implantation and prognosis in non-ischemic dilated cardiomyopathy. Int J Cardiol. 2018;250:195\u2013200.","journal-title":"Int J Cardiol"},{"key":"1166_CR37","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12968-021-00734-3","volume":"23","author":"S Ota","year":"2021","unstructured":"Ota S, Orii M, Nishiguchi T, Yokoyama M, Matsushita R, Takemoto K, et al. Implications of multiple late gadolinium enhancement lesions on the frequency of left ventricular reverse remodeling and prognosis in patients with non-ischemic cardiomyopathy. J Cardiovasc Magn Reson. 2021;23:32.","journal-title":"J Cardiovasc Magn Reson"},{"key":"1166_CR38","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.120.007944","volume":"14","author":"Y Xu","year":"2021","unstructured":"Xu Y, Li W, Wan K, Liang Y, Jiang X, Wang J, et al. Myocardial tissue reverse remodeling after guideline-directed medical therapy in idiopathic dilated cardiomyopathy. Circ Heart Fail. 2021;14: e007944.","journal-title":"Circ Heart Fail"},{"key":"1166_CR39","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1007\/s10741-015-9509-4","volume":"20","author":"A Barison","year":"2015","unstructured":"Barison A, Grigoratos C, Todiere G, Aquaro GD. Myocardial interstitial remodelling in nonischaemic dilated cardiomyopathy: insights from cardiovascular magnetic resonance. Heart Fail Rev. 2015;20:731\u201349.","journal-title":"Heart Fail Rev"},{"key":"1166_CR40","first-page":"143","volume":"51","author":"JM Krzesinski","year":"1996","unstructured":"Krzesinski JM, Rorive G, Cauwenberge V. Hypertension and left ventricular hypertrophy. Acta Cardiol. 1996;51:143\u201354.","journal-title":"Acta Cardiol"},{"key":"1166_CR41","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s00395-018-0668-z","volume":"113","author":"D Curley","year":"2018","unstructured":"Curley D, Lavin Plaza B, Shah AM, Botnar RM. Molecular imaging of cardiac remodelling after myocardial infarction. Basic Res Cardiol. 2018;113:10.","journal-title":"Basic Res Cardiol"},{"key":"1166_CR42","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1016\/j.jacc.2011.12.040","volume":"59","author":"C Jaarsma","year":"2012","unstructured":"Jaarsma C, Leiner T, Bekkers SC, Crijns HJ, Wildberger JE, Nagel E, et al. Diagnostic performance of noninvasive myocardial perfusion imaging using single-photon emission computed tomography, cardiac magnetic resonance, and positron emission tomography imaging for the detection of obstructive coronary artery disease: a meta-analysis. J Am Coll Cardiol. 2012;59:1719\u201328.","journal-title":"J Am Coll Cardiol"},{"key":"1166_CR43","doi-asserted-by":"publisher","first-page":"2984","DOI":"10.1093\/eurheartj\/ehq361","volume":"31","author":"N Ghosh","year":"2010","unstructured":"Ghosh N, Rimoldi OE, Beanlands RS, Camici PG. Assessment of myocardial ischaemia and viability: role of positron emission tomography. Eur Heart J. 2010;31:2984\u201395.","journal-title":"Eur Heart J"},{"key":"1166_CR44","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ccl.2013.09.002","volume":"32","author":"G Sayer","year":"2014","unstructured":"Sayer G, Bhat G. The renin-angiotensin-aldosterone system and heart failure. Cardiol Clin. 2014;32:21\u201332.","journal-title":"Cardiol Clin"},{"key":"1166_CR45","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1146\/annurev.pharmtox.010909.105610","volume":"50","author":"M Bader","year":"2010","unstructured":"Bader M. Tissue renin-angiotensin-aldosterone systems: targets for pharmacological therapy. Annu Rev Pharmacol Toxicol. 2010;50:439\u201365.","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"5","key":"1166_CR46","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1161\/01.CIR.95.5.1115","volume":"95","author":"B Hornig","year":"1997","unstructured":"Hornig B, Kohler C, Drexler H. Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans. Circulation. 1997;95(5):1115\u20138.","journal-title":"Circulation"},{"key":"1166_CR47","first-page":"502","volume":"104","author":"JR Reis Filho","year":"2015","unstructured":"Reis Filho JR, Cardoso JN, Cardoso CM, Pereira-Barretto AC. Reverse cardiac remodeling: a marker of better prognosis in heart failure. Arq Bras Cardiol. 2015;104:502\u20136.","journal-title":"Arq Bras Cardiol"},{"key":"1166_CR48","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1161\/01.CIR.86.2.431","volume":"86","author":"MA Konstam","year":"1992","unstructured":"Konstam MA, Rousseau MF, Kronenberg MW, Udelson JE, Melin J, Stewart D, et al. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators. Circulation. 1992;86:431\u20138.","journal-title":"Circulation"},{"key":"1166_CR49","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1056\/NEJM199209033271001","volume":"327","author":"MA Pfeffer","year":"1992","unstructured":"Pfeffer MA, Braunwald E, Moy\u00e9 LA, Basta L, Brown EJ Jr, Cuddy TE, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial. N Engl J Med. 1992;327:669\u201377.","journal-title":"N Engl J Med"},{"key":"1166_CR50","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1177\/1753944716642677","volume":"10","author":"CM Ferrario","year":"2016","unstructured":"Ferrario CM. Cardiac remodelling and RAS inhibition. Ther Adv Cardiovasc Dis. 2016;10:162\u201371.","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"1166_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.108660","volume":"114","author":"Y Ma","year":"2019","unstructured":"Ma Y, Yuan J, Hu J, Gao W, Zou Y, Ge J. ACE inhibitor suppresses cardiac remodeling after myocardial infarction by regulating dendritic cells and AT2 receptor-mediated mechanism in mice. Biomed Pharmacother. 2019;114: 108660.","journal-title":"Biomed Pharmacother"},{"key":"1166_CR52","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1067\/mhj.2000.105302","volume":"139","author":"MA Konstam","year":"2000","unstructured":"Konstam MA, Patten RD, Thomas I, Ramahi T, La Bresh K, Goldman S, et al. Effects of losartan and captopril on left ventricular volumes in elderly patients with heart failure: results of the ELITE ventricular function substudy. Am Heart J. 2000;139:1081\u20137.","journal-title":"Am Heart J"},{"key":"1166_CR53","doi-asserted-by":"publisher","unstructured":"Granger CB, McMurray JJ, Yusuf S, et al. CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet. 2003;362(9386):772\u20136. https:\/\/doi.org\/10.1016\/S0140-6736(03)14284-5","DOI":"10.1016\/S0140-6736(03)14284-5"},{"key":"1166_CR54","doi-asserted-by":"publisher","first-page":"R1","DOI":"10.1530\/JOE-14-0471","volume":"224","author":"MJ Young","year":"2015","unstructured":"Young MJ, Rickard AJ. Mineralocorticoid receptors in the heart: lessons from cell-selective transgenic animals. J Endocrinol. 2015;224:R1-13.","journal-title":"J Endocrinol"},{"key":"1166_CR55","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1056\/NEJMra000050","volume":"345","author":"KT Weber","year":"2001","unstructured":"Weber KT. Aldosterone in congestive heart failure. N Engl J Med. 2001;345:1689\u201397.","journal-title":"N Engl J Med"},{"key":"1166_CR56","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1146\/annurev-pharmtox-010814-124302","volume":"55","author":"A Lother","year":"2015","unstructured":"Lother A, Moser M, Bode C, Feldman RD, Hein L. Mineralocorticoids in the heart and vasculature: new insights for old hormones. Annu Rev Pharmacol Toxicol. 2015;55:289\u2013312.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"1166_CR57","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.mce.2011.06.038","volume":"350","author":"S Messaoudi","year":"2012","unstructured":"Messaoudi S, Azibani F, Delcayre C, Jaisser F. Aldosterone, mineralocorticoid receptor, and heart failure. Mol Cell Endocrinol. 2012;350:266\u201372.","journal-title":"Mol Cell Endocrinol"},{"key":"1166_CR58","doi-asserted-by":"publisher","first-page":"H2372","DOI":"10.1152\/ajpheart.00283.2011","volume":"301","author":"N L\u00f3pez-Andr\u00e9s","year":"2011","unstructured":"L\u00f3pez-Andr\u00e9s N, Martin-Fernandez B, Rossignol P, Zannad F, Lahera V, Fortuno MA, et al. A role for cardiotrophin-1 in myocardial remodeling induced by aldosterone. Am J Physiol Heart Circ Physiol. 2011;301:H2372\u201382.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"1166_CR59","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1097\/FJC.0b013e31820088ca","volume":"57","author":"B Mart\u00edn-Fern\u00e1ndez","year":"2011","unstructured":"Mart\u00edn-Fern\u00e1ndez B, de las Heras N, Miana M, Ballesteros S, Delgado C, Song S, et al. Structural, functional, and molecular alterations produced by aldosterone plus salt in rat heart: association with enhanced serum and glucocorticoid-regulated kinase-1 expression. J Cardiovasc Pharmacol. 2011;57:114\u201321.","journal-title":"J Cardiovasc Pharmacol"},{"key":"1166_CR60","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.yjmcc.2020.04.015","volume":"142","author":"M Tong","year":"2020","unstructured":"Tong M, Zablocki D, Sadoshima J. The role of Drp1 in mitophagy and cell death in the heart. J Mol Cell Cardiol. 2020;142:138\u201345.","journal-title":"J Mol Cell Cardiol"},{"key":"1166_CR61","doi-asserted-by":"publisher","first-page":"H2181","DOI":"10.1152\/ajpheart.00554.2011","volume":"301","author":"H Tsutsui","year":"2011","unstructured":"Tsutsui H, Kinugawa S, Matsushima S. Oxidative stress and heart failure. Am J Physiol Heart Circ Physiol. 2011;301:H2181\u201390.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"1166_CR62","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1161\/CIRCRESAHA.113.300308","volume":"113","author":"A Lymperopoulos","year":"2013","unstructured":"Lymperopoulos A, Rengo G, Koch WJ. Adrenergic nervous system in heart failure: pathophysiology and therapy. Circ Res. 2013;113:739\u201353.","journal-title":"Circ Res"},{"key":"1166_CR63","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1161\/HYPERTENSIONAHA.114.04488","volume":"65","author":"J Bauersachs","year":"2015","unstructured":"Bauersachs J, Jaisser F, Toto R. Mineralocorticoid receptor activation and mineralocorticoid receptor antagonist treatment in cardiac and renal diseases. Hypertension. 2015;65:257\u201363.","journal-title":"Hypertension"},{"key":"1166_CR64","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1097\/01.ASN.0000086472.65806.73","volume":"14","author":"TH Hostetter","year":"2003","unstructured":"Hostetter TH, Ibrahim HN. Aldosterone in chronic kidney and cardiac disease. J Am Soc Nephrol. 2003;14:2395\u2013401.","journal-title":"J Am Soc Nephrol"},{"key":"1166_CR65","doi-asserted-by":"publisher","first-page":"3764","DOI":"10.3390\/ijms19123764","volume":"19","author":"BM Parker","year":"2018","unstructured":"Parker BM, Wertz SL, Pollard CM, Desimine VL, Maning J, McCrink KA, et al. Novel insights into the crosstalk between mineralocorticoid receptor and G protein-coupled receptors in heart adverse remodeling and disease. Int J Mol Sci. 2018;19:3764.","journal-title":"Int J Mol Sci"},{"issue":"10","key":"1166_CR66","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341(10):709\u201317.","journal-title":"N Engl J Med"},{"key":"1166_CR67","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/NEJMoa030207","volume":"348","author":"B Pitt","year":"2003","unstructured":"Pitt B, Remme W, Zannad F, Eplerenone Post-Acute Myocardial Infarction Efficacy and Survival Study Investigators, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309\u201321.","journal-title":"N Engl J Med"},{"issue":"1","key":"1166_CR68","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1009492","volume":"364","author":"F Zannad","year":"2011","unstructured":"Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, EMPHASIS-HF Study Group, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364(1):11\u201321.","journal-title":"N Engl J Med"},{"key":"1166_CR69","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1161\/01.CIR.0000068316.53218.49","volume":"107","author":"S Reiken","year":"2003","unstructured":"Reiken S, Wehrens XH, Vest JA, Barbone A, Klotz S, Mancini D, et al. Beta-blockers restore calcium release channel function and improve cardiac muscle performance in human heart failure. Circulation. 2003;107:2459\u201366.","journal-title":"Circulation"},{"issue":"344","key":"1166_CR70","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1056\/NEJM200105313442201","volume":"31","author":"M Packer","year":"2001","unstructured":"Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, Carvedilol Prospective Randomized Cumulative Survival Study Group, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;31(344):1651\u20138.","journal-title":"N Engl J Med"},{"key":"1166_CR71","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1016\/S0140-6736(99)04440-2","volume":"353","author":"MERIT-HF Study Group","year":"1999","unstructured":"MERIT-HF Study Group. Effect of metoprolol CR\/XL in chronic heart failure: Metoprolol CR\/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001\u20137.","journal-title":"Lancet"},{"key":"1166_CR72","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0140-6736(98)11181-9","volume":"353","author":"CIBIS-II Investigators and Committees","year":"1999","unstructured":"CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353:9\u201313.","journal-title":"Lancet"},{"key":"1166_CR73","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.amjcard.2007.11.023","volume":"101","author":"G Flannery","year":"2008","unstructured":"Flannery G, Gehrig-Mills R, Billah B, Krum H. Analysis of randomized controlled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving beta-blockers. Am J Cardiol. 2008;101:865\u20139.","journal-title":"Am J Cardiol"},{"issue":"1","key":"1166_CR74","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15420\/ECR.2005.1g","volume":"1","author":"M Metra","year":"2005","unstructured":"Metra M, Nodari S, Dei CL. The role of beta blockade in heart failure. Eur Cardiol Rev. 2005;1(1):1\u20136.","journal-title":"Eur Cardiol Rev."},{"issue":"6","key":"1166_CR75","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1001\/jama.289.6.712","volume":"289","author":"H Krum","year":"2003","unstructured":"Krum H, Roecker EB, Mohacsi P, Rouleau JL, Tendera M, Coats AJ, Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group, et al. Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study. JAMA. 2003;289(6):712\u20138.","journal-title":"JAMA"},{"issue":"9266","key":"1166_CR76","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1016\/S0140-6736(00)04560-8","volume":"357","author":"HJ Dargie","year":"2001","unstructured":"Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001;357(9266):1385\u201390.","journal-title":"Lancet"},{"issue":"9377","key":"1166_CR77","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/S0140-6736(03)13800-7","volume":"362","author":"PA Poole-Wilson","year":"2003","unstructured":"Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, Carvedilol Or Metoprolol European Trial Investigators, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 2003;362(9377):7\u201313.","journal-title":"Lancet"},{"issue":"3","key":"1166_CR78","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1093\/eurheartj\/ehi115","volume":"26","author":"MD Flather","year":"2005","unstructured":"Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A, Borbola J, SENIORS Investigators, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26(3):215\u201325.","journal-title":"Eur Heart J"},{"key":"1166_CR79","doi-asserted-by":"crossref","unstructured":"Januzzi Jr JL, Prescott MF, Butler J, Felker GM, Maisel AS, McCague K, et al.; PROVE-HF Investigators. Association of change in N-terminal pro-B-type natriuretic peptide following initiation of sacubitril-valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction. JAMA. 2019 Sep 17;322(11):1085\u201395.","DOI":"10.1001\/jama.2019.12821"},{"issue":"6","key":"1166_CR80","doi-asserted-by":"publisher","first-page":"e006946","DOI":"10.1161\/CIRCHEARTFAILURE.119.006946","volume":"13","author":"JL Januzzi Jr","year":"2020","unstructured":"Januzzi JL Jr, Camacho A, Pi\u00f1a IL, Rocha R, Williamson KM, Maisel AS, PROVE-HF Investigators, et al. Reverse cardiac remodeling and outcome after initiation of sacubitril\/valsartan. Circ Heart Fail. 2020;13(6):e006946.","journal-title":"Circ Heart Fail"},{"issue":"8","key":"1166_CR81","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.754499","volume":"11","author":"D Pascual-Figal","year":"2021","unstructured":"Pascual-Figal D, Bay\u00e9s-Genis A, Beltr\u00e1n-Troncoso P, Caravaca-P\u00e9rez P, Conde-Martel A, Crespo-Leiro MG, et al. Sacubitril-valsartan, clinical benefits and related mechanisms of action in heart failure with reduced ejection fraction: a review. Front Cardiovasc Med. 2021;11(8): 754499.","journal-title":"Front Cardiovasc Med."},{"issue":"7","key":"1166_CR82","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.jacc.2018.11.042","volume":"73","author":"MR Zile","year":"2019","unstructured":"Zile MR, O\u2019Meara E, Claggett B, Prescott MF, Solomon SD, Swedberg K, et al. Effects of sacubitril\/valsartan on biomarkers of extracellular matrix regulation in patients with HFrEF. J Am Coll Cardiol. 2019;73(7):795\u2013806.","journal-title":"J Am Coll Cardiol"},{"key":"1166_CR83","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJ McMurray","year":"2014","unstructured":"McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, PARADIGM-HF Investigators and Committees, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993\u20131004.","journal-title":"N Engl J Med"},{"key":"1166_CR84","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1001\/jama.2019.12821","volume":"322","author":"JL Januzzi Jr","year":"2019","unstructured":"Januzzi JL Jr, Prescott MF, Butler J, James L, Butler MF, J, et al. Effects of sacubitril\/valsartan therapy on biomarkers, myocardial remodeling and outcomes (PROVE-HF). JAMA. 2019;322:1085\u201395.","journal-title":"JAMA"},{"key":"1166_CR85","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s11897-021-00501-6","volume":"18","author":"A Abboud","year":"2021","unstructured":"Abboud A, Januzzi JL. Reverse cardiac remodeling and ARNI therapy. Curr Heart Fail Rep. 2021;18:71\u201383.","journal-title":"Curr Heart Fail Rep"},{"key":"1166_CR86","doi-asserted-by":"publisher","first-page":"8684","DOI":"10.21037\/apm-21-157","volume":"10","author":"F Chen","year":"2021","unstructured":"Chen F, Tian G, Bai X, Li J, Yuan Z. The effect of sacubitril\/valsartan on cardiac function and cardiac remodeling in patients with heart failure with reduced ejection fraction. Ann Palliat Med. 2021;10:8684\u201391.","journal-title":"Ann Palliat Med."},{"key":"1166_CR87","volume":"35","author":"C Paolini","year":"2021","unstructured":"Paolini C, Mugnai G, Dalla Valle C, Volpiana A, Ferraglia A, Frigo AC, et al. Effects and clinical implications of sacubitril\/valsartan on left ventricular reverse remodeling in patients affected by chronic heart failure: a 24-month follow-up. Int J Cardiol Heart Vasc. 2021;35: 100821.","journal-title":"Int J Cardiol Heart Vasc."},{"key":"1166_CR88","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1093\/ehjcvp\/pvaa125","volume":"8","author":"YH Lee","year":"2022","unstructured":"Lee YH, Chiou WR, Hsu CY, Lin PL, Liang HW, Chung FP, et al. Different left ventricular remodeling patterns and clinical outcomes between non-ischemic and ischemic etiologies in heart failure patients receiving sacubitril\/valsartan treatment. Eur Heart J Cardiovasc Pharmacother. 2022;8:118\u201329.","journal-title":"Eur Heart J Cardiovasc Pharmacother."},{"key":"1166_CR89","doi-asserted-by":"publisher","first-page":"416","DOI":"10.3390\/medicina57050416","volume":"57","author":"HM Kim","year":"2021","unstructured":"Kim HM, Kim KH, Park JS, Oh BH. Beneficial effect of left ventricular remodeling after early change of sacubitril\/valsartan in patients with nonischemic dilated cardiomyopathy. Medicina. 2021;57:416.","journal-title":"Medicina"},{"key":"1166_CR90","volume":"27","author":"M Correale","year":"2020","unstructured":"Correale M, Mallardi A, Mazzeo P, Tricarico L, Diella C, Romano V, et al. Sacubitril\/valsartan improves right ventricular function in a real-life population of patients with chronic heart failure: the Daunia Heart Failure Registry. Int J Cardiol Heart Vasc. 2020;27: 100486.","journal-title":"Int J Cardiol Heart Vasc."},{"key":"1166_CR91","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1111\/cpf.12726","volume":"41","author":"M Correale","year":"2021","unstructured":"Correale M, Mazzeo P, Magnesa M, Fortunato M, Tricarico L, Leopizzi A, et al. Predictors of right ventricular function improvement with sacubitril\/valsartan in a real-life population of patients with chronic heart failure. Clin Physiol Funct Imaging. 2021;41:505\u201313.","journal-title":"Clin Physiol Funct Imaging"},{"key":"1166_CR92","doi-asserted-by":"crossref","unstructured":"Correale M, Mallardi A, Tricarico L, Mazzeo P, Ferraretti A, Diella C, et al. Remodelling is inversely proportional to left ventricular dimensions in a real-life population of patients with chronic heart failure after therapy with sacubitril\/valsartan. Acta Cardiol. 2021;6:1\u20136.","DOI":"10.1080\/00015385.2021.1950371"},{"key":"1166_CR93","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1161\/CIRCULATIONAHA.121.054892","volume":"144","author":"KF Docherty","year":"2021","unstructured":"Docherty KF, Campbell RT, Brooksbank KJM, Dreisbach JG, Forsyth P, Godeseth RL, et al. Effect of neprilysin inhibition on left ventricular remodeling in patients with asymptomatic left ventricular systolic dysfunction late after myocardial infarction. Circulation. 2021;144:199\u2013209.","journal-title":"Circulation"},{"key":"1166_CR94","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, DAPA-HF Trial Committees and Investigators, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381:1995\u20132200.","journal-title":"N Engl J Med"},{"key":"1166_CR95","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.cmet.2019.10.008","volume":"30","author":"DL Bhatt","year":"2019","unstructured":"Bhatt DL, Verma S, Braunwald E. The DAP-HF trial: a momentous victory in the war against heart failure. Cell Metab. 2019;30:847\u20139.","journal-title":"Cell Metab"},{"key":"1166_CR96","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, EMPA-REG OUTCOME Investigators, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117\u201328.","journal-title":"N Engl J Med"},{"key":"1166_CR97","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644\u201357.","journal-title":"N Engl J Med"},{"key":"1166_CR98","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu PL, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KW; CREDENCE Trial Investigators. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019;380:2295\u2013306.","journal-title":"N Engl J Med"},{"key":"1166_CR99","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.jacbts.2020.02.004","volume":"5","author":"GD Lopaschuk","year":"2020","unstructured":"Lopaschuk GD, Verma S. Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review. JACC Basic Transl Sci. 2020;5:632\u201344.","journal-title":"JACC Basic Transl Sci."},{"key":"1166_CR100","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1007\/s11886-019-1219-4","volume":"21","author":"C Wojcik","year":"2019","unstructured":"Wojcik C, Warden BA. Mechanisms and Evidence for Heart Failure Benefits from SGLT2 Inhibitors. Curr Cardiol Rep. 2019;21:130.","journal-title":"Curr Cardiol Rep"},{"key":"1166_CR101","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.cjca.2019.08.033","volume":"36","author":"S Kang","year":"2020","unstructured":"Kang S, Verma S, Hassanabad AF, Teng G, Belke DD, Dundas JA, et al. Direct effects of empagliflozin on extracellular matrix remodelling in human cardiac myofibroblasts: novel translational clues to explain EMPA-REG OUTCOME results. Can J Cardiol. 2020;36:543\u201353.","journal-title":"Can J Cardiol"},{"issue":"1","key":"1166_CR102","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12933-019-0816-2","volume":"18","author":"C Li","year":"2019","unstructured":"Li C, Zhang J, Xue M, Li X, Han F, Liu X, et al. SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart. Cardiovasc Diabetol. 2019;18(1):15.","journal-title":"Cardiovasc Diabetol"},{"key":"1166_CR103","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12933-016-0489-z","volume":"16","author":"J Habibi","year":"2017","unstructured":"Habibi J, Aroor AR, Sowers JR, Jia G, Hayden MR, Garro M, Barron B, Mayoux E, Rector RS, Whaley-Connell A, DeMarco VG. Sodium glucose transporter 2 (SGLT2) inhibition with empaglifozin improves cardiac diastolic function in a female rodent model of diabetes. Cardiovasc Diabetol. 2017;16:9.","journal-title":"Cardiovasc Diabetol"},{"key":"1166_CR104","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.jacbts.2017.07.003","volume":"2","author":"NJ Byrne","year":"2017","unstructured":"Byrne NJ, Parajuli N, Levasseur JL, Boisvenue J, Beker DL, Masson G, et al. Empagliflozin prevents worsening of cardiac function in an experimental model of pressure overload-induced heart failure. JACC Basic Transl Sci. 2017;2:347\u201354.","journal-title":"JACC Basic Transl Sci."},{"key":"1166_CR105","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12933-020-0994-y","volume":"19","author":"KA Connelly","year":"2020","unstructured":"Connelly KA, Zhang Y, Desjardins JF, Nghiem L, Visram A, Batchu SN, et al. Load-independent effects of empaglifozin contribute to improved cardiac function in experimental heart failure with reduced ejection fraction. Cardiovasc Diabetol. 2020;19:13.","journal-title":"Cardiovasc Diabetol"},{"key":"1166_CR106","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1093\/eurheartj\/ehy565.P1509","volume":"39","author":"S Pabel","year":"2018","unstructured":"Pabel S, Wagner S, Bollenberg H, Bengel P, Kov\u00e1cs \u00c1, Schach C, Tirilomis P, Mustroph J, Renner A, Gummert J, Fischer T, Van Linthout S, Tsch\u00f6pe C, Streckfuss-B\u00f6meke K, Hasenfuss G, Maier LS, Hamdani N, Sossalla S. Empaglifozin directly improves diastolic function in human heart failure. Eur Heart J. 2018;39:284\u20135.","journal-title":"Eur Heart J"},{"key":"1166_CR107","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s12933-019-0914-1","volume":"18","author":"N Zhang","year":"2019","unstructured":"Zhang N, Feng B, Ma X, Sun K, Xu G, Zhou Y. Dapagliflozin improves left ventricular remodeling and aorta sympathetic tone in a pig model of heart failure with preserved ejection fraction. Cardiovasc Diabetol. 2019;18:107.","journal-title":"Cardiovasc Diabetol"},{"key":"1166_CR108","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1093\/ajh\/hpz016","volume":"32","author":"L Shi","year":"2019","unstructured":"Shi L, Zhu D, Wang S, Jiang A, Li F. Dapagliflozin attenuates cardiac remodeling in mice model of cardiac pressure overload. Am J Hypertens. 2019;32:452\u20139.","journal-title":"Am J Hypertens"},{"issue":"9","key":"1166_CR109","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1080\/14779072.2020.1802247","volume":"18","author":"A Garcia-Ropero","year":"2020","unstructured":"Garcia-Ropero A, Santos-Gallego CG, Vargas-Delgado AP, Requena-Ibanez JA, Picatoste B, Ishikawa K, et al. Correlation between myocardial strain and adverse remodeling in a non-diabetic model of heart failure following empagliflozin therapy. Expert Rev Cardiovasc Ther. 2020;18(9):635\u201342.","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"1166_CR110","doi-asserted-by":"publisher","first-page":"e212","DOI":"10.2337\/dc16-1312","volume":"39","author":"S Verma","year":"2016","unstructured":"Verma S, Garg A, Yan AT, et al. Effect of empagliflozin on left ventricular mass and diastolic function in individuals with diabetes: an important clue to the EMPA-REG OUTCOME trial? Diabetes Care. 2016;39:e212\u20133.","journal-title":"Diabetes Care"},{"key":"1166_CR111","doi-asserted-by":"publisher","first-page":"3421","DOI":"10.1093\/eurheartj\/ehaa419","volume":"41","author":"AJM Brown","year":"2020","unstructured":"Brown AJM, Gandy S, McCrimmon R, Houston JG, Struthers AD, Lang CC. A randomized controlled trial of dapaglifozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial. Eur Heart J. 2020;41:3421\u201332.","journal-title":"Eur Heart J"},{"key":"1166_CR112","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1161\/CIRCULATIONAHA.119.042375","volume":"140","author":"S Verma","year":"2019","unstructured":"Verma S, Mazer CD, Yan AT, Mason T, Garg V, Teoh H, et al. Effect of empaglifozin on left ventricular mass in patients with type 2 diabetes and coronary artery disease: the EMPA-HEART CardioLink-6 randomized clinical trial. Circulation. 2019;140:1693\u2013702.","journal-title":"Circulation"},{"key":"1166_CR113","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12933-020-01209-y","volume":"20","author":"YW Yu","year":"2021","unstructured":"Yu YW, Zhao XM, Wang YH, Zhou Q, Huang Y, Zhai M, et al. Effect of sodium-glucose cotransporter 2 inhibitors on cardiac structure and function in type 2 diabetes mellitus patients with or without chronic heart failure: a meta-analysis. Cardiovasc Diabetol. 2021;20:25.","journal-title":"Cardiovasc Diabetol"},{"key":"1166_CR114","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.amjcard.2020.08.002","volume":"134","author":"D Patoulias","year":"2020","unstructured":"Patoulias D, Papadopoulos C, Katsimardou A, Kalogirou M-S, Doumas M. Meta-analysis assessing the effect of sodium-glucose co-transporter-2 inhibitors on left ventricular mass patients with type 2 diabetes mellitus. Am J Cardiol. 2020;134:149\u201352.","journal-title":"Am J Cardiol"},{"key":"1166_CR115","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.2337\/dc19-2187","volume":"43","author":"JSS Singh","year":"2020","unstructured":"Singh JSS, Mordi IR, Vickneson K, Fathi A, Donnan PT, Mohan M, et al. Dapagliflozin versus placebo on left ventricular remodeling in patients with diabetes and heart failure: the REFORM Trial. Diabetes Care. 2020;43:1356\u20139.","journal-title":"Diabetes Care"},{"key":"1166_CR116","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1161\/CIRCULATIONAHA.120.052186","volume":"143","author":"MMY Lee","year":"2021","unstructured":"Lee MMY, Brooksbank KJM, Wetherall K, Mangion K, Roditi G, Campbell RT, et al. Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF). Circulation. 2021;143:516\u201325.","journal-title":"Circulation"},{"key":"1166_CR117","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.jacc.2020.11.008","volume":"77","author":"CG Santos-Gallego","year":"2021","unstructured":"Santos-Gallego CG, Vargas-Delgado AP, Requena-Ibanez JA, Garcia-Ropero A, Mancini D, Pinney S, EMPA-TROPISM (ATRU-4) Investigators, et al. Randomized trial of empagliflozin in nondiabetic patients with heart failure and reduced ejection fraction. J Am Coll Cardiol. 2021;77:243\u201355.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"1166_CR118","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.jacc.2020.11.029","volume":"77","author":"LR Goldberg","year":"2021","unstructured":"Goldberg LR. The pleiotropic effects of SGLT2 inhibitors: remodeling the treatment of heart failure. J Am Coll Cardiol. 2021;77(3):256\u20138.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"1166_CR119","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jacbts.2018.10.002","volume":"4","author":"VG Lim","year":"2019","unstructured":"Lim VG, Bell RM, Arjun S, Kolatsi-Joannou M, Long DA, Yellon DM. SGLT2 inhibitor, canagliflozin, attenuates myocardial infarction in the diabetic and nondiabetic heart. JACC Basic Transl Sci. 2019;4(1):15\u201326.","journal-title":"JACC Basic Transl Sci."},{"key":"1166_CR120","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","volume":"382","author":"PW Armstrong","year":"2020","unstructured":"Armstrong PW, Pieske B, Anstrom KJ, Ezekowitz J, Hernandez AF, Butler J, VICTORIA Study Group, et al. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med. 2020;382:1883\u201393.","journal-title":"N Engl J Med"},{"key":"1166_CR121","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1056\/NEJMoa2025797","volume":"384","author":"JR Teerlink","year":"2021","unstructured":"Teerlink JR, Diaz R, Felker GM, McMurray JJV, Metra M, Solomon SD, et al. GALACTIC-HF Investigators. Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure. N Engl J Med. 2021;384:105\u201316.","journal-title":"N Engl J Med"},{"key":"1166_CR122","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1016\/j.jacc.2016.01.031","volume":"67","author":"JR Teerlink","year":"2016","unstructured":"Teerlink JR, Felker GM, McMurray JJV, Ponikowski P, Metra M, Filippatos GS, et al. Acute treatment with omecamtiv mecarbil to increase contractility in acute heart failure: the ATOMIC-AHF Study. J Am Coll Cardiol. 2016;67:1444\u201355.","journal-title":"J Am Coll Cardiol"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-022-01166-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-022-01166-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-022-01166-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T11:15:03Z","timestamp":1668424503000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-022-01166-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,20]]},"references-count":122,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["1166"],"URL":"https:\/\/doi.org\/10.1007\/s40261-022-01166-2","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,20]]},"assertion":[{"value":"26 April 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research received no external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interests"}},{"value":"\u00a0Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"MC, MI, NDB: ideation; PM, FC, MF, LT, MM, MA, SA, SF, VC, MM, GD: literature research and writing; PM: tables; PM, MM: figures; MC, NDB: coordinators; NDB: editing.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}